Trial Profile
A Two Year, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of Teriflunomide Administered Orally Once Daily in Pediatric Patients with Relapsing Forms of Multiple Sclerosis Followed by an Open-Label Extension
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 13 Sep 2023
Price :
$35
*
At a glance
- Drugs Teriflunomide (Primary)
- Indications Multiple sclerosis
- Focus Registrational; Therapeutic Use
- Acronyms TERIKIDS
- Sponsors Sanofi Genzyme
- 02 May 2023 The trial has been completed in France, according to European Clinical Trials Database record.
- 06 Apr 2023 The trial has been completed in Greece, according to European Clinical Trials Database record.
- 28 Jun 2022 Results presented at the 8th Congress of the European Academy of Neurology